Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Multiple Ascending Dose Study of E6742 in Healthy Japanese Adults
NCT04683185Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of e6742 in systemic lupus erythematosus (SLE) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Incidence of Treatment-emergent Adverse Events and Serious Adverse Events, Maximum Observed Plasma Concentration at Day 1 and 3 more. Started Dec 2020; status: completed.
02
Drugs
e6742
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04683185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683185.